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losing control over the examination. The
Board plans to address this issue at a future
meeting.

FUTURE MEETINGS:
August 21-22 in Sacramento.
November 20-21 in Los Angeles.

BOARD OF PHARMACY
Executive Officer: Patricia Harris
(916) 445-5014
Pursuant to Business and Professions
Code section 4000 et seq., the Board of
Pharmacy grants licenses and permits to
pharmacists, pharmacies, drug manufacturers, wholesalers and sellers of hypodermic needles. It regulates all sales of
dangerous drugs, controlled substances
and poisons. The Board is authorized to
adopt regulations, which are codified in
Division 17, Title 16 of the California
Code of Regulations (CCR). To enforce its
regulations, the Board employs full-time
inspectors who investigate accusations
and complaints received by the Board.
Investigations may be conducted openly
or covertly as the situation demands.
The Board conducts fact-finding and
disciplinary hearings and is authorized by
law to suspend or revoke licenses or permits for a variety of reasons, including
professional misconduct and any acts substantially related to the practice of pharmacy.
The Board consists of ten members,
three of whom are public. The remaining
members are pharmacists, five of whom
must be active practitioners. All are appointed for four-year terms.

MAJOR PROJECTS:
Attorney General Issues Opinion
Regarding Out-of-State Pharmacies. On
March 3, the Attorney General's Office
filed Opinion No. 91-305, responding to
the following three questions submitted
by Assemblymember Tricia Hunter: (])
whether California laws governing pharmacies apply to out-of-state mail order
pharmacies which fill prescriptions and
mail them to people in California; (2)
whether California's current regulation of
out-of-state mail order pharmacies is consistent with the commerce clause of the
U.S. Constitution; and (3) under California law, whether a generic type drug listed
on the negative drug formulary established by the Director of Health Services
may be substituted for a brand name drug
by an out-of-state pharmacy when filling
prescriptions and mailing them to people
in California. { 11:3 CRLR 101)
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The opinion answered all three questions affirmatively, under specified conditions. Regarding the first question, the
Attorney General noted that Business and
Professions Code section 4084.6 prohibits
an out-of-state pharmacy from doing business in California unless it obtains an outof-state distributor's license from the
Board of Pharmacy, or is registered with
the Board as a nonresident pharmacy. Outof-state drug distributors are required by
law to comply with Chapter 9 of the Business and Professions Code, which contains most of the statutes that govern pharmacies in California, and Division 21 of
the Health and Safety Code. Nonresident
pharmacies must comply with Business
and Professions Code sections 4050.1 and
4383, and Health and Safety Code section
11164. Thus, the opinion concluded that
California laws do apply in limited circumstances to out-of-state pharmacies
which fill prescriptions and mail them to
people in California; the extent of their
applicability depends on how the particular pharmacy is licensed.
Regarding California's regulation of
out-of-state pharmacies, the Attorney
General noted that in determining whether
a state-created impact on interstate commerce falls within permissible bounds, the
U.S. Supreme Court established a
"balancing test" in Pike v. Bruce Church
lnc., 397 U.S. 137, 142 (1970). Under that
test, where the statute regulates evenhandedly to effectuate a legitimate local
public interest, and its effects on interstate
commerce are only incidental, it will be
upheld unless the burden imposed on such
commerce is clearly excessive in relation
to the putative local benefits. According to
the opinion, a local purpose which has
traditionally been favored by the Court is
one promoting the health and safety of a
state's inhabitants. Based on its findings
that the state will be given considerable
latitude given the subject matter of the
regulation, the laws are applied indiscriminately to in- and out-of-state pharmacies, and the burden on interstate commerce is "clearly minimal in relation to the
legitimate state purpose of protecting the
health and welfare of California residents," the Attorney General's Office concluded that California's regulation of outof-state pharmacies does not offend the
Commerce Clause.
Regarding the third question, the Attorney General noted that, with certain
exceptions and qualifications, Business
and Professions Code section 4047.6 allows a pharmacist to substitute a generic
drug for a brand name drug when filling a
prescription. Business and Professions
Code section 4047.7 provides that one

such exception applies when the generic
drug type or drug product has been listed
on the "negative drug formulary" by the
Director of the Department of Health Services (OHS); if a drug is listed by the OHS
Director on the negative drug formulary, a
pharmacist may not substitute it for a
brand name drug. The Attorney General
found that compliance with section
4047.7 is required of all pharmacies in
California and any pharmacy licensed as
an out-of-state drug distributor pursuant to
Business and Professions Code section
4084.6. However, because pharmacies
registered as nonresident pharmacies need
comply only with Business and Professions Code sections 4050.1 and 4383 and
Health and Safety Code section 11164 in
order to maintain their registration and do
business in California, pharmacies
registered as nonresident pharmacies may
substitute a generic type drug listed on the
negative drug formulary established by
the OHS Director for a brand name drug
when filling prescriptions and mailing
them to people in California. According to
the opinion, however, no drug is currently
listed on the negative drug formulary.
FDA Clarifies Policy Regarding New
Drug Repacking. Last July, the Board
sought clarification of the U.S. Food and
Drug Administration's (FDA) Compliance Policy Guide (CPG) 7132c.06,
which states that "each step in the
manufacture and processing of a new drug
or antibiotic, from handling of raw ingredients to final packaging, must be approved by FDA, whether carried out by
the original manufacturer or by some subsequent handler or repacker of the
product. Pharmacists are not exempt from
these statutory requirements; however, the
agency regards mixing, packaging, and
other manipulations of approved drug
[sic] by licensed pharmacists, consistent
with the approved labeling of the product,
as an approved use of the product if conducted within the practice of pharmacy,
i.e., filling prescriptions for identified
patients." The Board asked FDA to clarify
whether "the breaking down of bulk drugs
for prescription or known need" constitutes manufacturing. Specifically, the
Board asked whether manipulation by a
pharmacist of an FDA-approved drug
constitutes manufacturing (which requires
registration as a manufacturer) when"(])
it is contrary to the manufacturer's package insert, or (2) it is prepared for a
specific patient in advance, but in anticipation of, a prescription, or (3) it is
prepared in anticipation of receiving one
or more prescriptions for the product, as
manipulated, but for a specific patient."
{12:1 CRLR 91; 11:4 CRLR 104)
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In March, the FDA issued CPG
7132. 16, entitled "Manufacture, Distribution, and Promotion of Adulterated,
Misbranded, or Unapproved New Drugs
for Human Use by State-Licensed Pharmacies," in which it clarified its position
on compounding by a pharmacy that is not
pursuant to a specific prescription. FDA
recognized that a licensed pharmacist may
compound drugs extemporaneously after
receipt of a valid prescription for an individual patient, and stated that "[p]harmacies that do not otherwise engage in
practices that extend beyond the limits set
forth in this CPG may prepare drugs in
very limited quantities before receiving a
valid prescription, provided they can
document a history of receiving valid
prescriptions that have been generated
solely within an established professional
practitioner-patient-pharmacy relationship, and provided further that they maintain the prescription on file for all such
products dispensed at the pharmacy as
required by state law."
However, FDA stated that it may, in the
exercise of its enforcement discretion, initiate federal enforcement actions against
entities and responsible persons when the
scope and nature of a pharmacy's activity
raises the kinds of concerns normally associated with a manufacturer and result in
significant violations of the new drug,
adulteration, or misbranding provisions of
the Federal Food, Drug, and Cosmetic
Act. In general, the FDA will consider the
following factors in determining whether
compounding by a pharmacy constitutes
manufacturing: whether the pharmacy advertises and solicits business from
prescribers and/or patients; whether the
pharmacy compounds more than it should
expect to use based on existing relationships and demands from prescribers;
whether there is an inordinate volume of
bulk drugs ordered or compounded drugs
dispensed compared to existing orders;
and whether the pharmacy manufactures
products that are readily available commercially or manufactures what are-in
effect-unapproved new drugs that vary
more than slightly from an FDA-approved
drug that is commercially available.
At its March meeting, the Board
reviewed FDA's new guide and found it
consistent with its own positions.
Patient Consultation Regulations. In
August 1990, the Office of Administrative
Law (OAL) approved the Board's adoption of new sections 1707 .1 and 1707 .2,
Di vision 17, Title 16 of the CCR, which
requires pharmacists to maintain patient
medication profiles for all ongoing
patient-consumers and to provide an oral
consultation to each patient or patient's

agent whenever a new prescription is dispensed, with specified exceptions. Although the regulations were originally
scheduled to take effect in March 1991,
the Board delayed the effective date until
January 1992 in order to provide pharmacists with additional time to prepare for
and phase in the changes to pharmacy
practice mandated by sections 1707. I and
1707.2.At a special December 1991 meeting, the Board voted to delay the effective
date of the regulations for a second time,
in response to claims that-more than one
year after their original approval-the industry was still unprepared to implement
the regulations. [12:1 CRLR 91 J
In order to comply with the Administrative Procedure Act, the Board
adopted an emergency regulation
suspending the implementation of the
provisions for 120 days. At its March 18
meeting, the Board conducted a public
hearing regarding its decision to change
the effective date to November I. At that
hearing, the Board received testimony
from the California Association of Public
Hospitals (CAPH) in support of the delay;
CAPH also advocated tying the effective
date of the oral consultation regulations to
the implementation of the pharmacy technician regulations, suggesting that the
consultation regulations take effect three
to six months after the Board's technician
regulations are approved (see supra}. Following the public hearing, the Board
adopted the proposed amendments to sections 1707 .1 and 1707 .2, delaying their
effective date until November I. The
Board submitted the rulemaking file to
OAL on April 21 and is awaiting OAL's
response.
Pharmacy Technicians. Pursuant to
AB 1244 (Polanco) (Chapter 841, Statutes
of 1991), the Board recently proposed the
adoption of regulations defining the functions and qualifications of pharmacy technicians, who may perform packaging,
manipulative, repetitive, or other nondiscretionary tasks while assisting, and while
under the direct supervision of, a
registered pharmacist. On January 21, the
Board conducted a public hearing on its
proposed amendments to section 1717(c)
and adoption of new sections 17931793. 7, Division 17, Title 16 of the CCR,
to define the qualifications and permissible duties of pharmacy technicians.
Existing section l 7 l 7(c) lists certain
duties which must be performed by a pharmacist and those duties which may be
performed by non-licensed personnel,
such as typing prescription labels and requesting and receiving refill authorization
subject to prior review by a pharmacist.
The Board proposes to incorporate por-
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tions of this section into new sections
1793.1 and 1793.3. Specifically, proposed
section 1793.1 would list functions which
only a pharmacist may perform and which
may not be delegated to a pharmacy technician; section 1793.2 would identify the
tasks which a pharmacy technician may
perform under the direct supervision and
control of a licensed pharmacist, including
removing drugs from stock, counting,
pouring, or mixing pharmaceuticals, placing the products into a container, affixing
labels to containers, packaging and
repackaging; and proposed section 1793.3
would describe and update tasks which
may be performed by non-licensed personnel who are not pharmacy technicians,
to include the entry of prescriptions into a
computer record system.
Proposed section 1793.4 would establish registration requirements for pharmacy technicians, and authorize the Board
to issue a certificate to an applicant who
has met any of the following requirements: has obtained at least an associate
of arts degree in a field of study directly
related to the duties performed by a pharmacy technician; has completed a training
course specified and approved by the
Board; is eligible to take the Board's pharmacist licensure exam; or has one year's
experience (a minimum of 1,500 hours)
performing the tasks of a pharmacy technician while assisting a pharmacist in the
preparation of prescriptions in specified
facilities. Section 1793.5 would specify
the training courses which are acceptable
to the Board in satisfaction of the requirement in section 1793.4. Section 1793.6
would establish requirements for pharmacies employing technicians; in particular, it clarifies that nonpharmacist personnel must work under the direct supervision of a registered pharmacist, the supervising pharmacist must be on the
premises at all times, and the pharmacist
must indicate that all prescriptions
prepared by a technician have been checked by initialing the prescription label
before the medication is given to the
patient. The subsection also requires a
technician to wear identification clearly
identifying him/her as a technician.
In response to comments from the industry, the Board modified its proposed
language in various significant respects.
For example, regarding technician
qualifications, the Board eliminated language which would have provided that a
person shall be deemed to have
"equivalent experience" if he/she has at
least three years of experience in a pharmacy and has passed an examination, as
specified. Instead, the modified language
provides that a person shall be deemed to
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have equivalent experience if he/she has
at least 1,500 hours of experience performing specified duties in a pharmacy in
the preceding three years.
Also, the Board increased from 120 to
240 the number of hours required to be
provided by specified technician training
courses seeking to be approved by the
Board. In addition, the Board eliminated a
requirement that such training programs
provide instruction on the general chemical and physical properties of drugs handled in a pharmacy.
The Board approved the language of
the regulations as modified, and released
it for a fifteen-day public comment period
which ended on February 14. Following
the public comment period and approval
by the Director of the Department of Consumer Affairs (DCA), the Board submitted the rulemaking file to OAL on
April 17.
Locked Storage and Emergency
Delivery Requirements for Medical
Device Retailers. On January 22, the
Board held a public hearing on its
proposed adoption of new sections 1748.1
and 1748.2, Title 16oftheCCR,regarding
the proper storage of dangerous devices at
medical device retailer (MOR) retail sites,
and the delivery of devices by MDRs to
patients after hours or in emergency situations. Since July 1991, the Board of Pharmacy has licensed MDRs as a separate
class. MDRs are non-pharmacy firms that
may dispense, upon prescription,
dangerous devices such as hypodermic
syringes and other items that are marked
by the manufacturer as available upon
prescription only. Each retail site of an
MOR must have a Board-licensed individual designated as "in charge." This
individual may be a pharmacist or an "exemptee," a separately-licensed individual
authorized to dispense dangerous devices.
Proposed section 1748. l would provide that an MOR may use locked storage
(a lock box or locked area) for the emergency dispensing of dangerous devices.
Locked storage may be installed or placed
in a service vehicle of the MOR for purposes of delivery, set-up, or after-hours
emergency service of dangerous devices
to patients having prescriptions on file for
the dangerous device. No hypodermic
needles or syringes may be stored in this
locked storage. Section 1748. l would also
provide that dangerous devices shall be
furnished from the locked storage only
upon the oral or written authorization of
an exemptee to an employee of the MOR
who operates the service vehicle; the service vehicle and the locked storage contained therein shall be locked at all times;
a current inventory and record of all
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dangerous devices placed into and furnished from the locked storage shall be
maintained by the MOR for three years;
within 72 hours of furnishing a dangerous
device from the emergency storage, the
exemptee shall be responsible for checking the contents of the locked storage and
noting the dangerous devices furnished on
the inventory; and the exemptee shall be
responsible for checking the contents of
the locked storage on a weekly basis.
Proposed section 1748.2 would permit
an MOR to keep a dangerous device in a
retail area of the premises during the absence of an exemptee, if the device is of
sufficient size and weight as to make
removal "difficult."
At the January 22 hearing, the Board
received comments urging it to relax
proposed section 1748. l, which appears to
limit emergency dispensing from the lock
box to "prescriptions on file for the
dangerous devices," and to preclude emergency dispensation for newly-prescribed
devices. The Board also received requests
to expand its definition of "exemptees" to
include licensed health care providers; an
exemptee is a person, other than a pharmacist, who is authorized to dispense
dangerous devices. The Board noted that
it is authorized to regulate dispensers, not
health care providers. It further noted that
OHS and other agencies regulate health
care providers and home health care agencies, and are responsible for their use of
dangerous devices for replacement or pursuant to a new prescription. The Board
then adopted the regulations as originally
proposed. At this writing, the rulemaking
file awaits review and approval by OAL.
Partial Filling of Schedule II
Prescriptions. As originally proposed,
new section 1745, Title 16 of the CCR,
would allow partial filling of Schedule II
controlled substance prescriptions for terminally ill patients who are in chronic
pain, under certain circumstances. Following a public hearing last October, the
Board modified its proposed language to
also allow partial filling when the
prescription is for an inpatient of a skilled
nursing facility; the Board released the
modified text for a fifteen-day comment
period. [12:1 CRLR 91] During that
period, the Board received comments
from the California Medical Association
(CMA ), which expressed concern over the
Board's use of the terms "chronic, continuing pain" and "terminally ill." In
response to CMA's concerns, the Board
deleted the chronic pain requirement and
revised the definition of "terminally ill" to
mean a patient for whom a licensed
physician has made and documented a
diagnosis of illness or disease that will

result in death. The Board released the
new language for an additional fifteen-day
comment period which ended on February
14. At this writing, the proposed section is
undergoing legal review prior to being
submitted to DCA and OAL.
Part-Time Pharmacist-in-Charge
Regulation. In 1991, the Board promulgated section 1709.1, Title 16oftheCCR,
which was developed to clarify statutory
requirements regarding the pharmacist-incharge; specifically, the regulation requires that this pharmacist have full
knowledge of the daily operations of a
pharmacy and specifies that a pharmacist
may be pharmacist-in charge at only one
pharmacy. According to the Board, after
the regulation took effect, it learned that
this situation had a negative impact on
several pharmacies which operate on a
part-time basis, with non-overlapping
hours, for which the sole pharmacist at
each served as pharmacist-in-charge at
both. To remedy this problem, the Board
published on April 10 notice of its intent
to amend section 1709.1 to allow a pharmacist to be the pharmacist-in-charge at
two pharmacies if only one of these pharmacies is open at any given time and if that
pharmacist is the only pharmacist at each
pharmacy. [ 12:1 CRLR 91-92]The Board
was scheduled to conduct a public hearing
on this amendment on May 27 in
Sacramento.
Other Regulatory Action. The following regulatory changes are also being pursued by the Board:
-Licensure of Drug Wholesalers. The
Board's proposed amendments to section
1780, which would change California's
requirements for drug wholesalers so that
they meet or exceed the standards of the
federal government under the Prescription
Drug Marketing Act of 1987, were submitted to OAL for approval on May 9.
[11:3 CRLR 101-{)2]
-Compounding for Office Use.
Proposed new section 1716. l defines the
quantity of compounded medication
which a pharmacist may furnish to a
prescriber for office use under Business
and Professions Code section 4046(c)(l).
Proposed new section 1716.2 specifies the
minimum types of records that pharmacies must keep when they furnish compounded medication to prescribers in
quantities larger than required for the
prescriber's immediate office use or when
a pharmacy compounds medication for
future furnishing. [11: 3 CRLR 102J These
proposed regulations were also submitted
to OAL for approval on May 9.
LEGISLATION:
SB 2044 (Boatwright), as amended
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April 2, would declare legislative findings
regarding unlicensed activity and
authorize all DCA boards, bureaus, and
commissions, including the Board of
Pharmacy, to establish by regulation a system for the issuance of an administrative
citation to an unlicensed person who is
acting in the capacity of a licensee or
registrant under the jurisdiction of that
board, bureau, or commission. [A.

CPGE&ED}
AB 3415 (Tucker), as amended May 7,
would exclude from the definition of
"dangerous devices" any prosthetic or orthopedic devices that do not require a
prescription. This bill would also delete an
existing provision of Jaw which requires
that any retailer who sells prosthetic or
orthotic dangerous devices on the
premises have a prescribed fitting room
under certain circumstances. [S. B&PJ
AB 3286 (Tucker), as amended May
13, would permit a medical device retailer
to dispense, furnish, transfer, or sell a
dangerous device to a licensed physical
therapist. [A. Floor] A similar bill, AB
2379 (Baker), was dropped by its author.
AB 2638 (Boland), as amended May
13, would exempt a chiropractor acting
within the scope of his/her license from
prohibitions against furnishing dangerous
drugs or devices. This bill would also provide that a medical device retailer may
dispense, furnish, transfer, or sell a
dangerous device to a licensed chiropractor. [A. Floor}
AB 2525 (Brown), as amended April
22, and SB 1418 (Moore), as amended
April 28, would each establish the Clean
Needle and Syringe Exchange Pilot
Project, and would authorize pharmacists,
physicians, and certain persons authorized
under the pilot project to furnish hypodermic needles and syringes without a
prescription or permit as prescribed
through the pilot project. {A. Floor, S.
Floor; respectivelyJ
SB 1986 (Marks), as introduced
February 21, would prohibit disability insurers that provide coverage for pharmaceutical services from requiring their
insureds or persons covered by the policy
to obtain pharmaceutical services exclusively from nonresident pharmacies,
and would provide that insurers may not
impose any limitations on coverage of
pharmaceutical services provided by instate pharmacies that are not also imposed
on nonresident pharmacies. [S.
InsCl&Corps]
AJR 63 (Bronzan), as amended May
7, would urge the President and Congress
to authorize the FDA to investigate a new
transitional drug category available only
through licensed pharmacists, with the

goal to decrease the time needed for the
FDA to approve a drug for over-thecounter status. [A. Health}
AB 3133 (Hunter), as amended April
27, would specify that no provision of law
prohibits the sale of dangerous devices to
licensed home health agencies and
licensed hospices, as defined. [S. B&PJ
AB 2743 (Lancaster), as amended
April 9, would amend Business and
Professions Code section 4038 to delete
the exemption of pharmacies and licensed
manufacturers from the definition of the
term wholesaler. [A. Floor}
AB 2070 (lsenberg), as amended
August 19, would generally make it unlawful for specified healing arts licensees
to refer a person to any laboratory, pharmacy, clinic, or health care facility solely
because the licensee has an ownership interest in the facility. However, a licensee
could make those referrals if the person
referred is the licensee's patient ofrecord,
there is no alternative provider or facility
available, and the licensee certifies that to
delay or forego the referral would cause
an unneeded health risk to the patient. [S.
Rules]
SB 664 (Calderon). Existing law
prohibits pharmacists, among others, from
charging, billing, or otherwise soliciting
payment from any patient, client, customer, or third-party payor for any clinical
laboratory test or service if the test or
service was not actually rendered by that
person or under his/her direct supervision,
unless the patient is apprised at the first
solicitation for payment of the name, address, and charges of the clinical
laboratory performing the service. As
amended March 12, this bill would also
make this prohibition applicable to any
subsequent charge, bill, or solicitation.
This bill passed both the Senate and the
Assembly and is currently awaiting
Senate concurrence in Assembly amendments.
AB 1226 (Hunter), as amended March
30, would repeal Business and Professions Code section 4047.7, which requires
the Director of the Department of Health
Services to establish a formulary of
generic drug types and drug products
which the Director determines
demonstrate clinically significant biological or therapeutic inequivalence and
which, if substituted, would pose a threat
to the health and safety of patients receiving medication if that medication is substituted by a pharmacist in lieu of a brand
name drug prescribed by a prescriber. [S.

B&PJ
AB 855 (Hunter). Under existing law,
registered pharmacists are required to inform patients of the harmful effects of the
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prescnpt10n drugs not previously dispensed to the patient, and to provide a
label or enclosure with the drug container
containing certain information. As
amended May 4, this bill would require
that a health facility ensure that each of its
patients receives a consultation from a
pharmacist, physician, or registered nurse
regarding medications received at the time
of discharge. [S. B&PJ
SB 917 (Kopp) would require certain
health care service plans that propose to
offer a pharmacy benefit or change their
relationship with pharmacy providers to
give written or published notice to pharmacy service providers of the plan's
proposal, and give those providers an opportunity to submit a bid to participate in
the plan's panel of providers on the terms
proposed. [A. Desk}
AB 819 (Speier). Existing law generally provides that it is not unlawful for
prescribed health care professionals to
refer a person to a laboratory, pharmacy,
clinic, or health care facility solely because the licensee has a proprietary interest or co-ownership in the facility. As
amended January 29, this bill would instead provide that it shall be unlawful for
these licensed health professionals to refer
a person to any diagnostic imaging center,
clinical laboratory, physical therapy or
rehabilitation facility, or psychometric
testing facility which is owned in whole or
in part by the licensee or in which the
licensee has a proprietary interest, and
would provide that disclosure of the
ownership or proprietary interest does not
exempt the licensee from the prohibition.
It would, however, permit specified
licensed health professionals to refer a
person to such a facility which is owned
in whole or in part by the licensee or in
which the licensee has a proprietary interest if the person referred is the licensee's
patient of record, there is no alternative
provider or facility available, and to delay
or forego the needed health care would
pose an immediate health risk to the
patient. [S. B&PJ
SB 1033 (Marks), which would have
permitted pharmacists to manufacture,
measure, fit to the patient, sell, and repair
medical devices without regard to whether
they bear a specified legend relating to a
federal prohibition against dispensing
without a prescription, died in committee.

LITIGATION:
In People v. Joseph Doss, No.
8046265 (Apr. I, 1992), the Second District Court of Appeal affirmed the conviction of Doss, a pharmacist and the owner
of Medical Memorial Pharmacy, for possession for sale of four controlled substan-
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ces. The court noted that the evidence,
taken in the light most favorable to the
judgment, established that Doss ordered
and took possession of large quantities of
certain controlled substances in high
dosages; the drugs were of a type rarely
prescribed by physicians but in high
demand among the illegal street trade. On
appeal, Doss contended that evidence was
legally insufficient to warrant its submission to the jury and factually insufficient
to sustain his convictions; Doss also challenged the trial court's denial of his motion
to suppress evidence obtained by the state
Board of Pharmacy inspector during his
audit of Doss' pharmacy records.
The Second District noted that "this
case squarely presents the issue whether a
pharmacist is immune from prosecution
for illegal possession of controlled substances, absent evidence he removed the
drugs from pharmacy premises." Doss
contended that Business and Professions
Code section 4230 immunizes him from
prosecution because he is a pharmacist
and there was no evidence he withdrew the
missing drugs from the pharmacy
premises; section 4230 provides that "[n]o
person shall have in possession any controlled substance, except that furnished to
such person upon the prescription of a
physician, dentist, podiatrist, or
veterinarian. The provisions of this section do not apply to the possession of any
controlled substance by a manufacturer or
wholesaler or a pharmacy or a physician
or podiatrist or dentist or veterinarian,
when in stock in containers correctly
labeled with the name and address of the
supplier or producer." The court rejected
Doss' arguments, stating that the "obvious
purpose of ... section 4230 is to authorize
the possession for sale of certain controlled substances by licensed pharmacists,
on pharmacy premises, to those holding
valid prescriptions. It does not confer
blanket immunity on a pharmacist to deal
drugs illegally from behind the counter or
to possess them with that intent." Finding
that section 4230 does not confer blanket
immunity on a pharmacist to possess controlled substances for any purpose on
pharmacy premises, the Second District
found that the case was properly submitted to the jury.
Next, the court examined the factual
sufficiency of the evidence. The
prosecution's evidence established that
from January 1987 through April 18,
1988, Doss' pharmacy ordered from one
pharmaceutical wholesaler 4,000 tablets
of Glutethimide (Doriden) in the highest
dosage available; at least three of the proof
of delivery slips appeared to bear Doss'
signature. During that same period, Doss'
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pharmacy ordered from another
wholesaler 2,500 Biphetamine, 1,200
Dilaudid, 2,800 Tuinal, and an additional
11,500 Glutethimide; these orders were
also for the strongest dosages available,
and a number of invoices and driver
manifests showing delivery of the four
drugs to Doss' pharmacy appeared to bear
the signature "J. Doss" as the person accepting the shipment. On April I 8, 1988,
following a report from a drug wholesaler
that Doss' pharmacy had ordered an excessive amount of Glutethimide, Board of
Pharmacy inspector Martin Levine conducted an audit of Medical Memorial
Pharmacy. That audit revealed that the
pharmacy had no purchase records for
Glutethimide, Biphetamine, Dilaudid, or
Tuinal; the pharmacy had no prescriptions
for the lawful distribution of any of the
four drugs during the period January 1987
through April 18; Doss had not performed
the Drug Enforcement Administration-required inventory for the period in question; and the pharmacy had none of the
four drugs in stock. Doss provided no
explanation for the missing drugs, and
said he was unaware of any thefts from the
pharmacy during the fifteen-month
period.
The Second District found that the jury
was entitled to conclude from the
evidence that Doss possessed the four
controlled substances for the purpose of
selling them outside the legitimate practice of his pharmaceutical business.
Noting the undisputed evidence showing
that the pharmacy ordered and received
the drugs and that Doss took possession of
some of them, that all of the drugs disappeared from the pharmacy without a single
record to account for their lawful distribution and without any report of a theft or
burglary, and that the drugs were of a kind
rarely prescribed by physicians but in
demand on the street and that Doss was
aware of such demand, the court concluded that the jury had "more than sufficient evidence to convict defendant on all
four counts."
Finally, Doss contended that the trial
court improperly refused to suppress
evidence gained from the audit conducted
by the Board of Pharmacy's inspector on
April 18, 1988. The trial court denied
Doss' motion to suppress the results of
Levine's audit, finding that Doss lacked a
reasonable expectation of privacy in the
pharmacy records; the court specifically
noted that the audit was conducted pur suant to Business and Professions Code
sections 4231 and 4232, which expressly
authorize warrantless inspections of highly regulated businesses.
The Second District affirmed the trial

court's denial of the motion to suppress,
noting that it is well settled that warrantless searches of pervasively regulated and
licensed businesses are permissible under
the Fourth Amendment, if conducted pursuant to statutory authorization. The
Second District stated that "[i]t is undisputed that pharmacies are closely regulated businesses in California. It is equally
clear that state statutes authorize administrative inspections of pharmacies."
The court concluded that under both the
statutory scheme and the circumstances of
this case, defendant had no reasonable
expectation of privacy in the pharmacy
records, and that given the pervasive
regulation of the pharmaceutical industry
and Doss' particular familiarity with it,
there can be no legitimate claim that he
maintained any expectation of privacy in
the pharmacy records.

RECENT MEETINGS:
At the Board's January meeting, staff
reported that the Department of Finance
had approved the following budget
change proposals, which have been included in the Governor's proposed 199293 budget: a $74,000 increase in funding
to the Pharmacist Recovery Program, the
Board's diversion program for substanceabusing licensees; $39,000 to add one
clerical position to the Licensing Unit to
process examination applications;
$45,000 to add one clerical position to the
Enforcement Unit on a limited-term basis;
$68,000 to produce an inspector procedure manual; and $145,000 to add one
Associate Governmental Program Analyst
and one Office Technician to implement
the pharmacy technician program, and one
office assistant to assist in the registration
of applicants. These changes must be approved by the legislature in its 1992-93
budget bill.
Also at its January meeting, the Board
heard a presentation from Rebecca Armato of Integrated Medical Systems, Inc.
(IMS), regarding the computerized transmission of prescriptions and refill
authorizations. IMS has developed Rx
Manager, a software program that allows
prescription and refill authorizations to be
transmitted between pharmacies and
physicians electronically over communication networks. The Board noted its
March 1990 policy decision stating that it
believes facsimile transmission of
prescriptions is legal and subject to the
same requirements as orally-transmitted
prescriptions. The Board then created a
subcommittee to formulate recommendations regarding proposed regulatory actions authorizing the electronic transmission of prescriptions and refill authoriza-
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REGULATORY AGENCY ACTION
tions.
At its March 18-19 meeting, the Board
discussed the recent recommendation of
the Legislative Analyst's Office (LAO) to
abolish all independent boards and
bureaus within DCA, replace them with
advisory boards, and consolidate the
licensing and enforcement functions of
these agencies into the Department; LAO
contends that such an action would increase the efficiency and cost-effectiveness of state regulation of trades and
professions. (See supra agency reports on
LAO and DCA for related discussion.)
Following a discussion, the Board unanimously agreed that its enforcement, consumer complaint handling, and licensing
functions should remain separate from a
consolidated unit within DCA, due to the
specialized nature of pharmacy enforcement and the increasingly sophisticated
nature of pharmacy practice.
Also at the March meeting, the Board
discussed a request from the California
Pharmacists Association (CPhA) to alter
the Board's enforcement procedure.
Specifically, CPhA had directed its staff to
work with Board staff to accomplish the
following changes: (I) before referral of
an administrative action against a licensee
to the Attorney General's Office, Board
staff would provide an opportunity for the
licensee to discuss the proposed action
with Board staff; and (2) Board staff
would provide notice to the licensee of
any referral to the Attorney General's Office. Executive Officer Patricia Harris
noted that throughout the investigation
process, every opportunity is given to the
licensee to provide information to the inspector. However, discussion of an investigation at the supervisory level would
probably bog down the system, increase
workload, and further delay an already
lengthy process. Harris recommended that
the Board not change the process as to do
so would be contrary to public policy. The
Board made no motion to amend its
process, instead suggesting that the Board
provide more education and information
about the enforcement process to alleviate
licensees' apprehensions without compromising investigations and administrative actions.

FUTURE MEETINGS:
October 14-15 in Los Angeles.

BOARD OF REGISTRATION FOR
PROFESSIONAL ENGINEERS
AND LAND SURVEYORS
Executive Officer: Darlene Stroup
(916) 920-7466

The Board of Registration for Professional Engineers and Land Surveyors
(PELS) regulates the practice of engineering and land surveying through its administration of the Professional Engineers
Act, sections 6700 through 6799 of the
Business and Professions Code, and the
Professional Land Surveyors' Act, sections 8700 through 8805 of the Business
and Professions Code. The Board's
regulations are found in Division 5, Title
16 of the California Code of Regulations
(CCR).
The basic functions of the Board are to
conduct examinations, issue certificates,
registrations, and/or licenses, and appropriately channel complaints against
registrants/licensees. The Board is additionally empowered to suspend or revoke
registrations/licenses. The Board considers the proposed decisions of administrative law judges who hear appeals
of applicants who are denied a registration/license, and those who have had their
registration/license suspended or revoked
for violations.
The Board consists of thirteen members: seven public members, one licensed
land surveyor, four registered Practice Act
engineers and one Title Act engineer.
Eleven of the members are appointed by
the Governor for four-year terms which
expire on a staggered basis. One public
member is appointed by the Speaker of the
Assembly and one by the Senate Rules
Committee.
The Board has established four standing committees and appoints other special
committees as needed. The four standing
committees are Administration, Enforcement, Examination/Qualifications, and
Legislation. The committees function in
an advisory capacity unless specifically
authorized to make binding decisions by
the Board.
Professional engineers are registered
through the three Practice Act categories
of civil, electrical, and mechanical engineering under section 6730 of the Business and Professions Code. The Title Act
categories of agricultural, chemical, control system, corrosion, fire protection, industrial, manufacturing, metallurgical,
nuclear, petroleum, quality, safety, and
traffic engineering are registered under
section 6732 of the Business and Professions Code.
Structural engineering and geotechnical engineering are authorities linked to
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the civil Practice Act and require an additional examination after qualification as a
civil engineer.
On February 24, Governor Wilson appointed Ted Fairfield to serve as the
Board's civil engineer member. Fairfield,
founder of a ci vii engineer consulting firm
in Pleasanton, has been registered as a
professional civil engineer in California
since 1962.

MAJOR PROJECTS:
Professional Land Surveyor Blue
Ribbon Panel Controversy. PELS currently administers its own land surveyor
examination, which is prepared by CTB
McMillan/McGraw Hill (CTB) under a
contract which extends until 1993. In October 1991, PELS passed a motion to
resume the use-as of April 1993--of the
national examination prepared by the National Council of Examiners for Engineering and Surveying (NCEES) for purposes
of licensing land surveyors. The Board
then appointed a blue ribbon panel of land
surveyors to review the national examination and develop a supplemental California-specific exam to be administered with
the national exam.
At PELS' February 14 meeting, Board
member David Slawson indicated that the
panel would recommend that PELS
postpone the use of the NCEES professional land surveyor exam until 1994. In
the interim, the panel recommended that
PELS retain the current examination
prepared by CTB. Following a lengthy
discussion, the Board tabled the matter
until its next meeting.
At its April 17 meeting, PELS resumed
its discussion regarding the panel's
recommendation. Additionally, the Board
discussed the apparently recent revelation
that many of the blue ribbon panel members had worked as subject matter experts
to develop and grade California's current
examination sold to the Board by CTB,
and had received reimbursement for
travel, lodging, and subsistence in excess
of $250 within the past twelve months
from CTB. Based on these facts, Department of Consumer Affairs (DCA) legal
counsel Don Chang opined that it may be
inappropriate for the Board to consider
some of the panel's recommendations.
However, by a vote of 8-4, PELS agreed
to postpone the implementation of the
NCEES and the California-specific
professional land surveyor exam to allow
for the reorganization and new membership of the blue ribbon panel, and to work
with NCEES to strengthen its exam; PELS
agreed to retain the current CTB exam in
the interim. The Board also directed Executive Officer Darlene Stroup to obtain
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